Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024

SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards

SAN DIEGO , Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc . (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych Congress 2025, taking place September 17-21 in San Diego . The results will be shared on September 18 , from 4:30 pm – 5:45 pm PT as part of a poster presentation session entitled "Latest Discoveries & Emerging Trends in MDD."

Osavampator (NBI-1065845) is an investigational selective positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid r

See Full Page